Cambridge Enterprise signs deal with Qkine Ltd to drive stem cell and regenerative medicine research
Qkine Ltd is a recent spin-out from the biochemistry department at the University of Cambridge. The company builds on protein production technologies for regenerative medicine.
This deal relates to Activin A production technology. The technology, which was developed by one of Qkine’s founders, Dr Marko Hyvönen, will be used to manufacture proteins that are used for the control of stem cell growth and differentiation.
Partner Nick Sutcliffe works with Cambridge Enterprise on their IP portfolio and has done patent work on the licensed Activin A technology.